Bluebird bio Inc (BLUE)

  • Volume:
  • Day's Range:
    5.20 - 5.68
  • 52 wk Range:
    2.87 - 25.39

BLUE Overview

Prev. Close
Day's Range
52 wk Range
Market Cap
Dividend (Yield)
Average Vol. (3m)
P/E Ratio
1-Year Change
Shares Outstanding
Next Earnings Date
Nov 03, 2022
What is your sentiment on Bluebird?
Vote to see community's results!

Bluebird bio Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Bluebird bio Inc Analysis

Bluebird bio Inc Company Profile

Bluebird bio Inc Company Profile


bluebird bio, Inc. is a biotechnology company. The Company is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s gene therapy programs in genetic diseases include programs for B-thalassemia; LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). It is using a lentiviral vector (LVV) platform, it custom designs each of its therapies to address the underlying cause of disease. The Company is developing lovotibeglogene autotemcel (lovo-cel) as a one-time treatment for patients with SCD, a genetic disease caused by a single mutation in the B-globin gene that leads to the production of abnormal sickle hemoglobin (HbS). The BLA for betibeglogene autotemcel (beti-cel) is for B-thalassemia in patients who receive regular red blood cell (RBC) transfusions.

Read More

Technical Summary

5 Min
15 Min
Moving AveragesBuySellSellStrong SellSell
Technical IndicatorsBuyNeutralStrong SellStrong SellStrong Sell
SummaryBuyNeutralStrong SellStrong SellStrong Sell
    • Con l'approvazione della FDA, bluebird ha anche annunciato l'intenzione di commercializzare Zynteglo negli Stati Uniti, per consentire ai pazienti di accedere al farmaco il prima possibile.Tuttavia, a causa della natura complessa della terapia genica, attualmente sarà disponibile esclusivamente presso i Centri di Trattamento Qualificati (QTC), che dispongono delle competenze necessarie nell'area in questione. I centri riceveranno anche una formazione specializzata per somministrare Zynteglo ai pazienti.La terapia genica, che rappresenta una potenziale cura per la beta-talassemia, sarà disponibile a un costo di acquisto all'ingrosso fissato dall'azienda di 2,8 milioni di dollari per paziente; il prezzo rappresenta il beneficio curativo della terapia.Tuttavia, Bluebird ha dichiarato che rimborserà le assicurazioni sanitarie statali e commerciali convenzionate fino all'80% del costo della terapia se questa smette di funzionare, fino a due anni dopo averla ricevuta.
      • and fall
    • will it go up?
      • yes
    • Slite brease...finally going UP like a Kite!!!
      • falling like a little stone down a chasm
        • The stock appears here at gaining .2% at 16.4 usd?
          • As if yesterday closing was 16:30!
        • Why so much down again?
          • TSVT tax-free dividend distribution
          • ok thanks, any value left on this or should we sell the old stock?
        • Dear bluebird bio, Inc. Stockholder:In January 2021, we announced a transformative milestone for bluebird bio, Inc.—our intent to separate our oncology portfolio and programs from our severe genetic disease portfolio and programs, thereby creating two independent, publicly traded companies. The strategic objectives of the separation are to unlock value, enhance operational performance and strategic flexibility and tailor the capital structures to best serve these distinct businesses.We believe the best way to realize the full potential of this separation is for bluebird bio, Inc. and 2seventy bio, Inc. to operate independently, with distinct management teams and boards of directors dedicated to their unique business strategies. Through this separation, we have the potential to create two focused, durable businesses that are well-positioned with the resources, talent and foundation to be industry leaders in their respective fields.Going forward, bluebird bio, Inc. intends to focus primarily on its programs in severe genetic disease, including betibeglogene autotemcel (beti-cel; formerly LentiGlobin gene therapy for β-thalassemia), LentiGlobin gene therapy for sickle cell disease, and elivaldogene autotemcel (eli-cel; formerly Lenti-D gene therapy for cerebral adrenoleukodystrophy). 2seventy bio, Inc. plans to focus primarily on the discovery and development of novel engineered cell therapies for cancer, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. 2seventy bio, Inc. expects to commercialize idecabtagene vicleucel (ide-cel; being commercialized as Abecma) in the United States and develop bb21217 through its collaboration arrangement with Bristol-Myers Squibb.Upon completion of the separation, 2seventy bio, Inc. will be spun out of bluebird bio, Inc. and established as an independent, publicly traded company. The separation is anticipated to be generally tax-free to bluebird bio, Inc. stockholders. Under the terms of the distribution, each bluebird bio, Inc. stockholder will receive one share of 2seventy bio, Inc. common stock for every three shares of bluebird bio, Inc. common stock held of record on October 19, 2021, the record date for the distribution. You do not need to take any action to receive the common stock of 2seventy bio, Inc. to which you are entitled as a bluebird bio, Inc. stockholder as of the record date.Please read the attached information statement, which is being shared with all bluebird bio, Inc. stockholders as of the record date for the distribution. It describes the separation in detail and contains important information about bluebird bio, Inc. and 2seventy bio, Inc.We thank you for your continued support of bluebird bio, Inc. Sincerely,Daniel S. LynchChairman of the Boardbluebird bio, Inc.
          • Dear Future 2seventy bio, Inc. Stockholder:On behalf of the entire future 2seventy bio, Inc. team, I am pleased to welcome you as a future stockholder of our new company.2seventy bio, Inc. will be a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. Its programs will be based on chimeric antigen receptor (CAR) technology and T cell receptor technology. At launch, 2seventy bio, Inc.’s programs will include idecabtagene vicleucel; ide-cel, or Abecma, and bb21217, CAR-T cell product candidates for the treatment of multiple myeloma, which are partnered under a collaboration arrangement with Bristol-Myers Squibb. We believe our team’s expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies will enable us to develop a pipeline of highly innovative, targeted cellular therapies for patients with cancer.Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “TSVT” in connection with the distribution of our company’s common stock by bluebird bio, Inc.I invite you to learn more about 2seventy bio, Inc. by reviewing the enclosed information statement. We look forward to our future as an independent company, and to your support as a 2seventy bio, Inc. stockholder as we begin this new and exciting chapter.Sincerely,Nick LeschlyChief Executive Officer2seventy bio, Inc.
            • Falling knife